Lung Cancer PatientsGDBlung70NCT06694194
Global, Regional, and National Burdens and Trends of Tracheal, Bronchial, and Lung Cancer in Individuals Aged 70 Years and Older from 1990 to 2021
An observational study of Lung Cancer Patients, run by Hongquan Xing.
Trial summary
Despite the increasing health burden of tracheal, bronchial, and lung (TBL) cancer patients aged ≥ 70 years worldwide, data on its burden and trends are limited. This study aimed to analyze the global, regional, and national burdens and trends of TBL cancer from 1990 to 2021. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Lung Cancer Patients
- How many people
- 111,627 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 1990to 10 Oct 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: patients with lung cancer and aged 70 years and older
Who may be able to join
- Pathologic Diagnosis of lung cancer
Who cannot join
- breast cancer Age less than 70 years
About this study
Despite the increasing health burden of tracheal, bronchial, and lung (TBL) cancer patients aged ≥ 70 years worldwide, data on its burden and trends are limited. This study aimed to analyze the global, regional, and national burdens and trends of TBL cancer from 1990 to 2021.
Read the detailed description
The latest cancer report indicates that tracheal, bronchial, and lung (TBL) cancer, the most widespread cancer globally, accounts for 12.4% of new diagnoses and 18.7% of cancer-related deaths, thereby presenting significant societal, public health, and economic challenges.Despite the increasing health burden of tracheal, bronchial, and lung (TBL) cancer patients aged ≥ 70 years worldwide, data on its burden and trends are limited. This study aimed to analyze the global, regional, and national burdens and trends of TBL cancer from 1990 to 2021.
- Conditions
- Lung Cancer Patients
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| NA | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
The incidence, mortality, and disability-adjusted life years (DALYs) data for TBL cancer patients aged ≥ 70 years, spanning 1990-2021.
We extracted the incidence, mortality, and disability-adjusted life years (DALYs) for TBL cancer in individuals aged ≥ 70 years and above along with their 95% uncertainty intervals (UIs) from the GBD 2021 database (https://vizhub.healthdata.org
/gbd-results/). The data were stratified by age groups and social determinants of the health index (SDI) regions, encompassing 21 global GBD regions and 204 countries.
Measured: 1990-2021
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Nov 2024
- Study start1 Jan 1990
- Primary completion10 Oct 2024
- Study completion10 Oct 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Cancer PatientsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 111,627 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hongquan Xing
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Hongquan Xing, Nanchang University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06694194
- Sponsor's protocol ID
- NanchangUN
- Acronym
- GDBlung70
- Status last verified
- Jan 1990
- First submitted
- 11 Nov 2024
- Last updated
- 19 Nov 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Global, Regional, and National Burdens and Trends of Tracheal, Bronchial, and Lung Cancer in Individuals Aged 70 Years and Older from 1990 to 2021
- ClinicalTrials.gov ID
- NCT06694194
- Acronym / sponsor ID
- GDBlung70 / NanchangUN
- Conditions
- Lung Cancer Patients
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 111,627 participants (actual)
- Lead sponsor
- Hongquan XingUniversity, hospital or other
- Study start
- 1 Jan 1990 (actual)
- Primary completion
- 10 Oct 2024 (actual)
- Study completion
- 10 Oct 2024 (actual)
- First posted
- 19 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Despite the increasing health burden of tracheal, bronchial, and lung (TBL) cancer patients aged ≥ 70 years worldwide, data on its burden and trends are limited. This study aimed to analyze the global, regional, and national burdens and trends of TBL cancer from 1990 to 2021.
Detailed description
The latest cancer report indicates that tracheal, bronchial, and lung (TBL) cancer, the most widespread cancer globally, accounts for 12.4% of new diagnoses and 18.7% of cancer-related deaths, thereby presenting significant societal, public health, and economic challenges.Despite the increasing health burden of tracheal, bronchial, and lung (TBL) cancer patients aged ≥ 70 years worldwide, data on its burden and trends are limited. This study aimed to analyze the global, regional, and national burdens and trends of TBL cancer from 1990 to 2021.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| NA | – | – |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- patients with lung cancer and aged 70 years and older
Key inclusion criteria (1 listed)
- Pathologic Diagnosis of lung cancer
Key exclusion criteria (1 listed)
- breast cancer Age less than 70 years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The incidence, mortality, and disability-adjusted life years (DALYs) data for TBL cancer patients aged ≥ 70 years, spanning 1990-2021.
Time frame: 1990-2021
We extracted the incidence, mortality, and disability-adjusted life years (DALYs) for TBL cancer in individuals aged ≥ 70 years and above along with their 95% uncertainty intervals (UIs) from the GBD 2021 database (https://vizhub.healthdata.org /gbd-results/). The data were stratified by age groups and social determinants of the health index (SDI) regions, encompassing 21 global GBD regions and 204 countries.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Nov 2024.
Related trials for Lung Cancer Patients
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
RecruitingObservational study
Patient-Specific MRD Liquid Biopsy in Resected NSCLC: Plasma and Bronchial Washing ctDNA
Non-Small Cell Lung Cancer, Minimal Residual Disease
Active, not recruitingPhase 2
Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC
Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer Patients, run by Hongquan Xing.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The incidence, mortality, and disability-adjusted life years (DALYs) data for TBL cancer patients aged ≥ 70 years, spanning 1990-2021. (time frame: 1990-2021). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Nov 2024.